Uncoupling Metastasis and Epithelial‐to‐Mesenchymal Transition in sgP19/kRAS‐Driven Spontaneous Metastatic Liver Tumor Model
Advanced Science · 2026-02 · 13 (8)
DOI: 10.1002/advs.202514198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 07.12.2025. Verfasst von Jingwen Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Medicine, Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100069, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Liver Neoplasms, Cholangiocarcinoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Epithelial‐to‐mesenchymal transition (EMT) is an early event during tumor metastasis. Here, the relevance of EMT in liver carcinogenesis and metastasis is sought to be determined in a murine mixed typical intrahepatic cholangiocarcinoma (iCCA)/sarcomatoid iCCA liver tumor model using CRISPR/Cas9‐based gene deletion of p19 ( sgP19) in combination with transposon‐based expression of the activated form of pCaggs‐kRAS G12D ( kRAS) in the mouse liver ( sgP19/kRAS mixed model). It discovered that metastasis in the lymph node, lung, or kidney occurred in the sgP19/kRAS mixed model. Both typical iCCA tumor cells with epithelial features and sarcomatoid tumor cells with mesenchymal features could be detected in this model. Lineage tracing technology is applied to confirm the metastasis induced in the sgP19/kRAS model. Subsequently, the gain of expression of mesenchymal marker vimentin in tumor cells revealed the induction of EMT in the sgP19/kRAS model, and it is induced by activating the TGFβ/ZEB1 signaling pathway. Altogether, the study suggests that TGFβ/ZEB1 mediates the induction of EMT in iCCA, while targeting EMT failed to inhibit iCCA development or tumor metastasis, disputing the claims that EMT is a major molecular event leading to tumor metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Traditional Chinese Medicine, Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100069, China.
- Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu Province, 210008, P. R. China.
- Department of Gastroenterology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, 210008, P. R. China.
- Cancer Biology Program, University of Hawai'i Cancer Center, University of Hawai'i, Honolulu, Hawaii, HI 96813, USA.
- Department of General Surgery, The Second Affiliated Hospital of Xi'an Jiaotong University, Xian, Shaanxi Province, 710004, P. R. China.
- Department of Cell and Tissue Biology, UCSF, San Francisco, CA, CA 94143, USA.
ORCID-Profile: Xin Chen
Förderung
- NCI NIH HHS
Zitieren
APA
Wang, J., Xu, Z., Xu, L., Wang, L., Geng, J., Wang, X., Xu, M., Superville, D., Reeves, M., Evert, M., Calvisi, D. F., Chen, X., & Song, X. (2026). Uncoupling Metastasis and Epithelial‐to‐Mesenchymal Transition in sgP19/kRAS‐Driven Spontaneous Metastatic Liver Tumor Model. Advanced Science, 13(8). https://doi.org/10.1002/advs.202514198
Vancouver
Wang J, Xu Z, Xu L, Wang L, Geng J, Wang X, et al. Uncoupling Metastasis and Epithelial‐to‐Mesenchymal Transition in sgP19/kRAS‐Driven Spontaneous Metastatic Liver Tumor Model. Advanced Science. 2026;13(8). doi:10.1002/advs.202514198
BibTeX
@article{Wang2026,
author = {Wang, Jingwen and Xu, Zijing and Xu, Lei and Wang, Lishan and Geng, Jiahao and Wang, Xue and Xu, Meng and Superville, Daphne and Reeves, Melissa and Evert, Matthias and Calvisi, Diego F and Chen, Xin and Song, Xinhua},
title = {Uncoupling Metastasis and Epithelial‐to‐Mesenchymal Transition in sgP19/kRAS‐Driven Spontaneous Metastatic Liver Tumor Model},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {8},
doi = {10.1002/advs.202514198}
}
EUVIMED